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Direct sequencing of segments of the envelope gene of human immunodeficiency virus type 1 proviruses in
peripheral blood mononuclear cells has revealed that a cohort of hemophiliacs who were infected after exposure
to a single common batch of factor VIII share closely related virus strains. Seventy-four sequences extending
from hypervariable regions V4 through V5 from nine patients yielded a mean intrapatient nucleotide distance
of 5.5%, while a mean of 4.2% was observed in 39 sequences of the V3 loop (six patients). Phylogenetic analysis
revealed that sequences of six Edinburgh patients were particularly closely related and those from a patient
infected in the United States were very distinct. The mean nucleotide distance among these six was 8.3%, while
the mean distance from the U.S.-derived sequences was 25.5% in the V4-V5 region. The rate of sequence
change across this patient group has been estimated to be 0.4% per year in the V4-V5 region and 0.5% per year
in the V3 region, with at least a twofold range across patients. Only two inactivating nucleotide substitutions
have been observed in a total of 42 kb of sequence obtained from the env and gag genes during this study.
Human immunodeficiency virus type 1 (HIV-1) is charac-
terized by extensive genomic heterogeneity. Independent
isolates from North America differ in almost 10% of amino
acid residues in env, while isolates from Africa can differ in
up to 25% of these sites (1, 30). In common with visna virus
and equine infectious anemia virus (3, 23), HIV-1 also shows
variability within infected individuals. Genetic differences
have been observed among consecutive isolates and, con-
currently, within the same isolate established from the same
patient (9, 26). It has previously been suggested in the case
of the other lentiviruses that sequence change may be
immunologically driven, natural selection favoring the
spread of variants that escape from immune surveillance
during the course of the infection (2, 20). If sequence
changes in HIV occur under the influence of selection by the
host immune response, their identity and rate of occurrence
will be important for the effort to develop an effective
vaccine.
Previous attempts to estimate the rate of evolution of the
HIV-1 genome have been based on analyses of sequence
data obtained from viral isolates made at different times. One
group (29) suggested from an analysis of env sequences that
HIV-1 and HIV-2 may have diverged as recently as 40 years
ago. Others (34; P. M. Sharp and W.-H. Li, Nature [London]
336:315, 1988), using data on gag and pol as well, suggested
that the two viruses diverged from 150 to 300 years ago.
Hahn et al. (9) obtained three isolates from the same patient
over an 18-month period and analyzed the env gene se-
quences obtained in a similar way. Their estimate of the rate
of sequence change is compatible with all of these.
We have been studying HIV sequence change in a group
of patients who became infected during 1984 after exposure
* Corresponding author.
to factor VIII concentrate prepared from donated blood by
the Scottish National Blood Transfusion Service (SNBTS).
A single batch of factor VIII was implicated in the serocon-
version of these patients (17). Of a total of 32 patients
exposed to the batch, 18 seroconverted. These patients
received, on average, significantly more units of the putative
infected batch than those who did not (17). This batch was
prepared from plasma collected at a time when HIV-1 was
only beginning to enter the donor population, as indicated by
the low incidence of anti-HIV-1-positive sera among samples
collected at that time (24). For both these reasons it has been
considered that very few HIV-infected individuals could
have contributed to the infected plasma pool.
We have analyzed HIV sequences in samples donated in
the summer of 1989 by eight members of this cohort and one
other HIV-infected hemophiliac. We have used a double
polymerase chain reaction (PCR) procedure to obtain the
nucleotide sequence of individual provirus molecules (27).
This approach is not subject to any bias due to virus culture
in vitro nor to possible errors introduced by Taq polymerase
(31). Between 5 and 14 sequences from each patient studied
were obtained from one region of gag encoding part of p24
and from two regions of env; one, V4-V5, which includes the
CD4-binding domain (4, 12) and the flanking hypervariable
regions (V4 and V5; 19), and another which spans the
immunodominant or V3 loop (19, 25). We have investigated
the evolutionary relationships among sequences from dif-
ferent patients and found that they are much more closely
related to each other than are sequences from independent
isolates or sequences obtained from the noncohort control.
We will present evidence that at least six of the cohort
patients were infected by virus originating from a single
individual donor. On this basis we have estimated the extent
of divergence in these regions of the HIV-1 genome among
this group of patients and the rate of sequence change.
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MATERIALS AND METHODS
Patients studied. Heparinized whole blood (20 ml) was
obtained from each of eight patients treated solely with
SNBTS-prepared factor VIII who seroconverted during 1984
and from 1 hemophiliac infected in the United States. The
circumstances of infection and details of the HIV-1 antigen
and antibody status of the cohort have been described
previously (17, 28). The current clinical status is described
elsewhere (R. Cuthbert, C. A. Ludlam, C. M. Steel, J.
Tucker, D. Beatson, S. Rebus, and J. F. Peutherer, Br. Med.
J., in press).
HIV primers. Oligonucleotides were synthesized by the
Oswel DNA Service, Department of Chemistry, University
of Edinburgh, and were purified by high-pressure liquid
chromatography. The sequences of the primers are given,
along with their positions in HIV HXB2 in parentheses (+,
sense; -, antisense). V3: -a-, TACAATGTACACATGGA
ATT (+, 6957); -b-, TGGCAGTCTAGCAGAAGAAG (+,
7009); -c-, CTGGGTCCCCTCCTGAGG (-, 7331); and -d-,
ATTACAGTAGAAAAATTCCCC (-, 7381). V4-V5: -e-,
TCAGGAGGGGACCCAGAAATT (+, 7316); -f-, GGGG
AATTTTTCTACTGTAAT (+, 7360); -g-, CTTCTCCAATT
GTCCCTCATA (-, 7665); and -h-, CCATAGTGCTTCCTG
CTGCT (-, 7814).
PCR amplification. DNA samples were prepared from at
least 5 x 106 peripheral blood mononuclear cells (PMBCs).
DNA preparation, amplification by double PCR, and quan-
tification by limiting dilution were carried as described
previously (27). All DNA extractions and amplification re-
actions carried appropriate negative controls (blood from
seronegative, low-risk group blood donors) to detect con-
tamination at every stage in the procedure. To permit the
same sample to be amplified in two regions, the first reaction
used the positive-sense outer V3 primer -a- with the an-
tisense outer V4-V5 primer -h- to amplify an 858-bp frag-
ment. The second reaction amplified an aliquot of the
product using the inner V3 sense -b- and inner V4-V5
antisense -g- primers to give a 657-bp fragment. The final
amplifications used the inner V3 and V4-V5 primers in
separate reactions. V3 and V4-V5 DNAs amplified by this
modified procedure are equivalent to those prepared by
conventional amplification of separate samples by the double
PCR.
Determination of sequence. The double PCR procedure
allows the amplification of segments of single isolated mol-
ecules of HIV-1 provirus to yield quantities sufficient for
direct sequencing (>500 ng of DNA). The DNA product of
PCR amplification was purified by using Gene-Clean (Bio
101 Inc.). From 50 ,ul of PCR amplification a yield of 500 ng
was routinely achieved, of which 100 ng was used for each
set of sequencing reactions. Sequencing was carried out by
using Sequenase protocols (U.S. Biochemicals) except as
follows. The standard annealing mix was adjusted to 10%
dimethyl sulfoxide (33), denatured by boiling (5 min), and
chilled to 0°C. The labeling reaction was performed at room
temperature for 5 min with only two of the usual three
unlabeled dNTPs present at 0.25 ,iM and 5 ,uCi of [35S]dATP
or [35S]dCTP (1,000 Ci/mM) (32). The choice of labeled
nucleotide was based on nucleotide usage 3' to the priming
site used. Termination reaction mixtures were adjusted to
10% dimethyl sulfoxide, and the termination was performed
at 37°C for 5 min. The sequences were analyzed on 6%
wedge sequencing gels.
Sequences were collected and aligned using the University
of Wisconsin GCG package (5) and the Needleman and
Wunsch alignment algorithm (21). Final alignments were
adjusted by eye, and their quality was assessed by the
reduction of the total branch lengths of the phylograms
generated under the assumption of maximum parsimony.
Because of the volume of data available it was not
practicable to perform a maximum likelihood analysis of the
sequence data itself. The data were therefore transformed
into a distance matrix, using a modification of the distance
algorithm of Kimura (10) which takes into account the base
composition of the DNA under study (11). Comparison of
results obtained by maximum likelihood analysis of subsets
of the data showed good agreement with those given by
using the distance matrix approach.
Phylogenetic trees were generated from the distance ma-
trix by the method of Fitch and Margoliash (7), using the
Phylip package (6) distributed by J. Felsenstein. Final tree
topologies were permuted by using a branch swapping
algorithm to minimize overall length.
Nucleotide sequence accession number. The sequences pre-
sented in this report have been submitted to GenBank under
accession number M36997.
RESULTS
Nucleotide sequences from PBMCs. In Fig. 1 we present 74
nucleotide sequences of the V4-V5 region obtained directly
from double PCR-amplified PBMC DNAs of eight members
of the Edinburgh hemophiliac cohort and one control pa-
tient, also a hemophiliac, who was infected in the United
States. We include for comparison published sequences
from eight independent HIV isolates. In Fig. 2, 39 sequences
of the V3 region obtained similarly from five of the cohort
members and the control patient are given. Each sequence
represents an individual provirus molecule, isolated by limit
dilution of the PBMC DNA. Because it is possible to amplify
more than one region of the same molecule using this
procedure, in many cases we have been able to obtain
sequences of both V4-V5 and V3 from the same provirus.
The sequences were aligned by the introduction of gaps as
necessary. As the positions and lengths of gaps were con-
strained to preserve the reading frame, the alignment was
initially carried out on the deduced amino acid sequences.
Absence of inactivating substitutions. The sequences of the
V4-V5 region exhibit extensive variation due both to nucle-
otide substitutions and to insertion-deletion events, as indi-
cated by the need to introduce a large number of gaps in the
alignment (Fig. 1). Despite this, only two inactivating sub-
stitutions were observed in the 74 sequences (each approx-
imately 300 bp in length). There are no inactivating muta-
tions among the 39 V3 region sequences shown in Fig. 2 (325
bp in length). We have also determined 33 sequences of a
220-bp segment of the gag (p24) gene (coordinates 1407 to
1646 in the HXB2 sequence) from five cohort and three
noncohort patients (data submitted to Los Alamos AIDS
data base). No inactivating mutations were observed in these
sequences. In this data set, therefore, the frequency of
inactivating substitutions is approximately 1 in 20 kb.
These results suggest that in these regions of gag and env
there is strong selection for maintenance of a continuous
reading frame. The strength of selection favoring the existing
amino acid sequence is indicated by the ratio of synonymous
to nonsynonymous substitutions (13, 14), which we have
estimated by using the procedure of Li et al. (16). For gag
the ratio is 6.7, indicating that the amino acid sequence is
under significant constraints. For the V4-V5 and V3 regions
the ratios are 1.3 and 0.92, respectively. These extremely
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FIG. 1. Nucleotide sequence of the V4-V5 region of gpl20 in 74 HIV-1 provirus molecules from Edinburgh hemophiliacs. Sequences are
grouped by patient number and an identifying letter. Sequences of the equivalent region from eight independent HIV isolates obtained from
the Los Alamos AIDS data base are shown below for comparison. Gaps inserted during alignment are indicated by dashes. Regions for which
the sequence has not been determined for a particular provirus are shown by dots. See Materials and Methods for experimental procedures.
Sequence continues on the following pages.
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low ratios indicate that the amino acid as well as the
nucleotide sequence of gp120 is evolving very rapidly (13).
The limit to the rate of sequence evolution appears to be the
requirement to maintain an intact reading frame.
We have calculated the overall frequency of transitions
and transversions for all pairwise comparisons among these
sequences. The ratio of transition to transversion substitu-
tions was 1.79 for the V4-V5 region and 1.50 in the gag
sequence, comparable to ratios observed for mammalian
genes (22).
Evolutionary relationships among HIV sequences. Exami-
nation of Fig. 1 reveals, as might be expected, that se-
quences from the same patients are often more similar to
each other than are sequences from different patients. In
order to quantify the extent of evolutionary divergence
between sequences we have estimated nucleotide distances
from the observed percent nucleotide sequence identity,
using the model of Kimura (10), which allows for different
rates of transition and transversion substitutions. The mean
intrapatient and interpatient nucleotide distances have then
been used to estimate the phylogenetic relationships among
all 74 V4-V5 and 39 V3 sequences (see Materials and
Methods). Representative maximum parsimony trees depict-
ing these relationships are given in Fig. 3 (V4-V5) and 4 (V3).
Several points emerged directly from the phylogenetic
analysis. (i) For both regions, sequences from any particular
patient group most closely with other sequences from the
same patient. (ii) The sequences from the noncohort control
(patient 12) are unrelated to those of any other patient and
group more closely with those from North American iso-
lates. (iii) Sequences from six patients (no. 77, 79, 83, 84, 87,
and 91) group together very closely and in some cases are
interspersed. (iv) Among the Edinburgh sequences, those
from patients 74 and 82 are much less closely related to those
from the other patients in both regions of env. Patient 82 is as
distant from all other Edinburgh sequences in V4-V5 as the
U.S.-infected control (no. 12). On the other hand, sequences
from patient 74 which cluster together with those from the
central six Edinburgh cohort samples (see above) in V4-V5
do not do so in V3.
Nucleotide distances of HIV sequences within and between
patients. We estimated the evolutionary divergence for all
pairwise comparisons among the sequences in Fig. 1 and 2.
We then grouped the estimates into (i) comparisons between
sequences derived from a single patient and (ii) comparisons
between sequences taken from each pairwise combination of
patients, and we examined the distribution of distances for
each. For most groups the distribution of estimates was
relatively narrow and unimodal (data not shown), but for
some, specifically for patient 74 and for the group of HIV
isolates, a wider spread was observed. The group means are
given in Tables 1 and 2.
The mean nucleotide distance in V4-V5 between HIV
isolates (17.0%) was considerably higher than that for the
intrapatient comparisons. The mean intrapatient distance
among all patients was 5.5% (range 1 to 9.2%). Amnong the
Edinburgh patients, the mean nucleotide distances of several
interpatient pairs, e.g., 5.6% for patients 83 and 84, were
within this range. However, the U.S.-infected control (pa-
tient 12) had very distinct HIV sequences, as did patient 82.
In V3, for which the mean distance within patients was
similar (4.2%), all the nucleotide distances between patients
were much greater. It should be noted that our estimates of
divergence are based solely on the extent of nucleotide
substitution. In regions such as V4, for which DNA insertion
0.00 0.05 0.1 0 0.15 0.20
FIG. 3. Phylogenetic relationships of the V4-V5 region of the
HIV-1 env gene from Edinburgh hemophiliacs. The tree was ob-
tained by using a maximum parsimony procedure on the basis of the
nucleotide distances summarized in Table 1. The scale bar shows
the proportion of nucleotides substituted for a given horizontal
branch length. See Materials and Methods for procedures.
and deletion events are also frequent, these will be underes-
timates of the overall mutation distance.
In Table 3 we present estimates obtained in a similar
fashion for the region sequenced in gag. As expected from
J.VIROL.
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FIG. 4. Phylogenetic relationships of the V3 region of the HIV-1
env gene from Edinburgh hemophiliacs. The tree was obtained in the
same way as that shown in Fig. 3, using the data summarized in
Table 2.
previous work, the overall mean within-patient diversity is
much lower, at only 1.65%. It is interesting to note that the
patient showing the greatest diversity in this region also had
relatively high diversity in env, but the figures for gag are too
low to contain much information on phylogenetic relation-
ships.
Divergence of HIV-1 sequences within the hemophiliac
cohort. The phylogenetic analyses presented in Fig. 2 and 3
TABLE 2. Nucleotide distances in the V3 region of HIV-1
among Edinburgh hemophiliacsa
Nucleotide distance
Patient Patient no. HIVo.HI
12 74 77 82 87 91 isolates
12 0.0378
74 0.1572 0.0354
77 0.1858 0.1217 0.0321
82 0.1618 0.0912 0.1228 0.0328
87 0.2183 0.1375 0.0943 0.1371 0.0498
91 0.2183 0.1335 0.1005 0.1480 0.0939 0.0614
HIV isolates 0.2192 0.1608 0.1894 0.1525 0.1868 0.2125 0.2000
a Calculated from the data given in Fig. 2. See Materials and Methods and
Table 1, footnotes a through c.
indicate that the sequences obtained from most of these
patients are distinct from those of any other, despite the
close relationships between those from several patients.
Thus, the evolutionary divergence that is represented by the
within-patient nucleotide distances has occurred during the
period of infection, which is approximately 5 years, although
we cannot know exactly when divergence occurred within
that time. If we assume that divergence occurred immedi-
ately after infection, then we might estimate the rate of
sequence change in these regions of gpl20 by dividing the
mean nucleotide distance between sequences from the same
patient by the length of time those sequences might have
been evolving independently (twice the time since infection).
Using the data in Table 1, we would obtain a mean estimate
of 0.55% per annum.
An estimate of sequence change in HIV-1 obtained in this
way depends also on the assumptions (i) that the rate of
change is constant and (ii) that it is the same in each patient.
An estimate which did not depend on these assumptions
would be preferable. To avoid the need to make these
assumptions, we have adopted a model of HIV evolution in
the cohort with which we can use information on the
nucleotide distances between patients as well as within them
(Fig. 5). As indicated above, six of the patients studied show
interpatient mean distances which overlap the within-patient
diversity. In addition, these six patients share a specific
TABLE 1. Nucleotide distances in the V4-V5 region of HIV-1 among Edinburgh hemophiliacsa
Nucleotide distance
Patient Patient no. Provirus Clinical statusno. ______________________________________ HIV abundanced CDC stage'
12 74 77 79 82 83 84 87 91 isolatesc
12 0.0529 1/400 II
74 0.2429 0.0920 1/2,000 IVC2
77 0.2205 0.1115 0.0379 1/2,500 IVA
79 0.2665 0.1381 0.0820 0.0728 1/3,300 IVC2
82 0.3160 0.2254 0.2599 0.2852 0.0729 1/700 II
83 0.2581 0.1052 0.0669 0.0882 0.2454 0.0380 1/14,000 Il
84 0.2643 0.1075 0.0720 0.0701 0.2691 0.0556 0.0095 1/10,000 1VC2f
87 0.2776 0.1278 0.0866 0.1098 0.2516 0.0779 0.0731 0.0652 1/600 IVC2
91 0.2454 0.1196 0.0787 0.0960 0.2376 0.0898 0.0808 0.1106 0.0493 1/2,700 IVC2
HIV isolates 0.2080 0.1766 0.1781 0.2030 0.2748 0.1687 0.1893 0.1950 0.1731 0.1701
a Distances calculated from the data given in Fig. 1 as described in Materials and Methods. On diagonal, mean distances from all pairwise intrapatient
comparisons. Below diagonal, mean distances from all pairwise interpatient comparisons.
b Patient infected in the United States after exposure to commercial factor VIII.
Data from the group of eight independent HIV-1 isolates whose sequences are included in Fig. 1.
d HIV-1 provirus abundance in each PBMC DNA sample was estimated by limit dilution (27).
Clinical status of each patient at the time of sampling.
f Given in error as CDC stage II previously (27).
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TABLE 3. Nucleotide distances in gag p24 among
Edinburgh hemophiliacsa
Nucleotide distance
Patient Patient no. HIVo.HI
74 77 79 82 83 84 isolate
74 0.0151
77 0.0261 0.0101
79 0.0177 0.0178 0.0150
82 0.0419 0.0376 0.0370 0.0407
83 0.0359 0.0153 0.0271 0.0391 0.0051
84 0.0278 0.0120 0.0145 0.0324 0.0214 0.0133
HIV isolate 0.0320 0.0434 0.0361 0.0567 0.0489 0.0442 0.0489
a See Materials and Methods and Table 1, footnotes a through c, for details.
Calculated from data submitted to the Los Alamos AIDS data base.
sequence motif in V4 which is readily recognizable in the
amino acid sequence (26a). We interpret this result as
indicating that they were infected with HIV sequences which
originated from a single donor. On the other hand, patients
74 and 82 show much larger nucleotide distances from other
Edinburgh patients and have done since seroconversion
(L.-Q. Zhang and P. Simmonds, unpublished data). On this
basis they are not strong candidates for infection from the
same donor. We have therefore analyzed the data excluding
those from patients 74 and 82.
Two components comprise the total sequence change in
each patient (Fig. 5), one representing the within-patient
divergence and a second comprising the sequence change
that occurred prior to the time when the sequences present
within the patient diverged from each other. In the case of
patient A (Fig. 5), these are represented by a and d. Sets of
simultaneous equations allow the unknown components d, e,
and f to be estimated, using data for each of the inter- and
intrapatient comparisons, represented by a, b, and c and
b
C c
a)
FIG. 5. Model of HIV sequence evolution in the hemophiliac
cohort. In this model patients are indicated by A, B, and C, and the
branch lengths of the individual components of the tree are indicated
by a through f. The upper parts of the branches in each case
represent sequence divergence among the samples obtained, and the
branch length is taken as 1/2 the mean sequence distance within each
sample. Then, if the mean interpatient nucleotide distances are
indicated by AB, AC, BC, we obtain:
AC -AB + BC
fV= 2 -c
and e = BC - b - c -fand d = AC - a - c -f. The total sequence
change that has occurred in patient A is then given by a + d and
likewise for the other patients. Estimates of these parameters for six
hemophiliac patients are given in Table 4.
TABLE 4. Evolutionary divergence in the V4-V5 region, the V3
region, and gag among Edinburgh hemophiliacsa
Patient Branch Branch Totallength length branch
no. (d) (a)b (d + a)
V4-V5 region
77 0.0157 0.0190 0.0347
79 0.0132 0.0364 0.0492
83 0.0137 0.019 0.0327
84 0.0212 0.005 0.0262
87 0.0200 0.0326 0.0526
91 0.0274 0.025 0.0524
V3 region
77 0.0343 0.0161 0.0506
87 0.0190 0.0250 0.044
91 0.0193 0.0308 0.0501
gag
77 0.002 0.0051 0.0071
79 0.0008 0.0075 0.0083
83 0.012 0.0026 0.0146
84 0.0002 0.0067 0.0069
a Estimated from the model described in the legend to Fig. 5, using the data
from Tables 1, 2, and 3.
b Calculated by dividing the mean intrapatient nucleotide distance by 2.
AB, AC, and BC, respectively. The unknown branch length
d can be estimated from any of 10 sets of three-way
comparisons. We have taken the mean of all 10 and give
these as our estimates for V4-V5 and V3 (Table 4). The
branch components, e.g., a and d for patient A (Fig. 5), can
then be summed for each patient to give the total HIV
sequence evolution in these patients. We have also calcu-
lated the branch lengths for the gag sequences for five of the
patients in the same way (Table 4).
By this approach we estimate the mean branch length
separating the sequences from these patients to be 4.12%
(V4-V5) and 4.82% (V3). We have used both synonymous
and nonsynonymous substitutions to obtain this estimate,
because their ratio is close to unity in these regions. The
range of branch lengths varies approximately twofold over
patients in V4-V5 but less so in V3; however, fewer patients
can be compared in that region. Comparable branch lengths
in gag are much shorter because of the low frequency of
amino-acid replacement substitutions (Table 4).
The extent of HIV sequence evolution in each patient is
depicted in Fig. 6. Triangles represent the divergence ob-
served between sequences in the same sample (Fig. 5, a).
The vertical distance below the triangles represents prior
divergence (Fig. 5, d) from the sequence in the infected
donor (represented by the origin). Thus, patients 79 and 87,
who show the greatest intrapatient nucleotide distance of
this group, also contain sequences that appear to be most
distant from the origin. In contrast, patient 84 shows the
lowest intrapatient nucleotide distance but a greater change
from the origin than does patient 79. All three patients were
Centers for Disease Control (CDC) stage IVC2 when sam-
pled, and all patients had been infected for approximately 5
years.
DISCUSSION
Low frequencies of inactivating mutations. It has recently
been suggested that a high proportion, even a majority, of
HIV proviral genomes must be defective. In a 216-nucleotide
J. VIROL.
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FIG. 6. HIV-1 sequence evolution among six hemophiliacs in-
fected by exposure to a common batch of factor VIII. The estimates
of mean branch length in Table 4 are plotted as a set of indepen-
dently evolving virus populations which shared a common ancestor
in the infected donor. Vertical distance is directly proportional to
the estimated mean sequence change in each patient. The inverted
triangles indicate the observed intrapatient sequence divergence for
each patient (Fig. 5, a). The vertical distance from the root to the
(inverted) apex of each triangle indicates the inferred evolutionary
change (Fig. 5, d).
(72-amino-acid) segment of the first exon of the tat gene,
Meyerhans et al. (18) observed four inactivating mutations in
35 sequences (total of 7,000 nucleotides, approximately).
This gives a frequency of 5 x 10-4 per nucleotide, which is
about 10-fold higher than the 5 x 10-5 we have observed in
42,000 nucleotides sequenced from gag and env. A number
of defective gag and env sequences have been described by
the same group, but these were obtained from isolates
propagated in tissue culture (8). Meyerhans et al. (18) also
observed a further eight variants which gave no Tat activity
in vitro. It was suggested that up to a third of tat genes, and
perhaps a majority of HIV-1 proviruses are inactive. How-
ever, the data we have presented indicate that the extension
to the rest of the HIV genome is not justified. In the regions
of gag- and env-encoding structural proteins that we have
sequenced, the frequency of defective sequences is much
lower than that found in tat.
Our earlier work (27) led us to conclude that the copy
number of HIV-1 provirus in circulating PBMCs was close to
one. We argued that functional complementation would not
be possible within an infected cell and so we would not
expect a high proportion of proviruses to be defective
because they would continually be exposed to a strong
selection for function. The results we have presented here
confirm that even in the most variable regions of the HIV-1
genome there is only a very low frequency of inactivating
mutations. We conclude that, in the peripheral circulation,
proviruses defective in env or gag do not play an important
role in the pathogenesis of HIV-1.
Source of infection. The particular value in studying the
rate and pattern of sequence change in HIV-1 among these
patients arises from two features. First, as for many hemo-
philiacs and other patients, the dates of seroconversion and
likely dates of infection are known. Second, a single batch of
factor VIII which was prepared by the SNBTS has been
implicated in the infection of these patients (17), who had no
other known risk factors. This batch was given to all but 1 of
16 patients who seroconverted between March and May
1984 and to 2 others who seroconverted later. In contrast,
the next most likely batch was only given to nine of the
patients who seroconverted at that time. None of the pa-
tients had received commercial factor VIII. There were,
however, two other patients who seroconverted at that time
who had not received either commercial factor VIII or the
implicated batch.
A total of 32 patients were exposed to this batch, and the
probability of seroconversion was significantly associated
with the number of vials used (17). Whereas 8 of 9 patients
who used more than 40 vials became infected, only 7 of 23
who used less did so. In addition, it seems likely that only a
very few HIV-infected individuals contributed to that batch
as only small numbers of HIV seropositives have been
identified among sera obtained from the major risk groups in
the collection area during 1983, when the plasma pool was
being collected (24). On both counts, the implicated batch of
SNBTS factor VIII does not appear to have been highly
infectious.
As documented here and elsewhere (8, 9, 18, 26), HIV-
infected individuals harbor many different viral sequences,
but those present at any one time usually bear a close
relationship to each other. In the case of the implicated
factor VIII batch, the patients who seroconverted may have
received a minimum infectious dose. Sampling small num-
bers of HIV sequence variants in this way from those
present in the infected donor(s) could cause them to be
unevenly distributed among the recipients. The hemophiliac
patients studied might therefore have become infected with
viruses whose genomes were already differentiated. How-
ever, if members of the cohort were infected with virus
which originated from a single individual, they would pos-
sess HIV sequences that, although not identical, would be
much more similar to each other than to those from unre-
lated individuals. If more than one infected donor contrib-
uted to the infected batch, then two or more groups of
sequences might be distributed among the recipients.
Pattern of HIV sequence relationships within the Edinburgh
hemophiliac cohort. We have analyzed a total of 74 se-
quences from the CD4-binding domain of env and flanking
hypervariable regions V4 and V5 (19), which we obtained by
limit dilution, amplification, and direct sequencing of the
product (27). The phylogenies given in Fig. 3 and 4, which
were obtained from nucleotide distance matrices, were sim-
ilar to others produced by a maximum-likelihood procedure
(see Materials and Methods). All the phylogenetic analyses
showed, first, that sequences from the same patient are more
similar to each other than to those from different patients.
Second, the noncohort patient, who was infected in the
United States from commercial factor VIII, has sequences
which are very distinct from those of the cohort patients, as
are all the published sequences from viral isolates. Third, in
the V4-V5 region, six of the eight Edinburgh-infected hemo-
philiacs have sequences which are particularly closely re-
lated to each other, while two others (no. 82 and 74) have
sequences which are less so.
Diversity within patients. The nucleotide diversity ob-
served within individual patients varied over a wide range.
Within the V4-V5 region the mean nucleotide distance
between sequences obtained from patient 84 was 1%, while
that from patient 74 was 9.2%. The overall mean sequence
divergence within patients was 5%. We have examined the
distribution of nucleotide distances among sequences from
the same patients by plotting histograms of the results of all
pairwise sequence comparisons (data not shown). We would
in this way be able to detect whether there was evidence for
any patient, and patient 74 in particular, having been in-
fected with virus originating from more than one donor,
which would be revealed as a bimodal distribution of nucle-
otide distances (see above). We did not detect such bimo-
dality in any patient. There is therefore no evidence from the
VOL. 64, 1990
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distribution of nucleotide distances that any of these patients
have received virus from more than one donor.
It has been suggested that the diversity of HIV sequences
to be found within a sample might increase as the patient
progresses into acquired immunodeficiency syndrome (M.
Nowak, R. M. May, and R. M. Anderson, personal commu-
nication). For several of these patients, we earlier deter-
mined proviral abundance in terms of the number of PBMCs
calculated to contain one HIV provirus, and this also might
influence sequence diversity. In Table 1 the clinical status
and proviral abundance of each patient is given. There is no
apparent association with either variable. The samples at the
extremes of the range of diversity are both CDC stage IVC2.
The patient with the lowest mean diversity did have a low
proviral abundance, but was not the lowest, and the two
CDC stage II patients in the data set were as variable as most
others. We conclude that no relationship between diversity
and these variables can be established on the basis of these
data.
Origin of HIV infection of the Edinburgh hemophiliac
cohort. We have identified a group of six patients (no. 77, 79,
83, 84, 87, and 91) among whose HIV sequences there is a
very close relationship (Tables 1 and 2). The mean of the
interpatient nucleotide distances among these six is 8.25%.
This is close to the intrapatient diversity observed for
patients 79, 82, and 87, less than that found for patient 74,
and about half that found in this region for independent HIV
isolates (Table 1). All of the Edinburgh-infected patients are
very divergent from the U.S.-infected control patient, al-
though, as mentioned above, two of them grouped less
closely to the other six. The clustering on the basis of
nucleotide distance is supported by the absence in patients
74 and 82 of a specific oligopeptide motif in the V4 region
which is common to the six most closely related patients
(26a). We interpret the sequence data as indicating that these
six patients were indeed infected with virus that originated
from a single individual.
The two more-divergent Edinburgh-infected patients were
also unusual in their seroconversion data. One (no. 82)
seroconverted after exposure to a much lower dose than that
received by most of those who became HIV seropositive
after exposure to the implicated batch of factor VIII. The
other (no. 74) seroconverted a very long time after exposure.
In both cases, we have recently obtained evidence that their
current distinctiveness is not due to very rapid sequence
change; sequences from free virus in stored plasma from the
time of seroconversion are similarly distinct (L.-Q. Zhang,
unpublished data). We have recently found sequences simi-
lar to those of patient 82 in two more Edinburgh hemophil-
iacs (data not shown), one of whom also seroconverted in
1984 but did not receive any of the common batch. We
therefore suggest that three patients may have been infected
independently of the others at about the same time. The
origin of the virus present in patient 74 is unclear and will
require wider analysis of samples from patients who sero-
converted in Scotland in 1983-1984.
Rate of HIV sequence evolution. The unusual circum-
stances surrounding the infection of these patients have
permitted a direct interpretation of the divergence of HIV
sequences from different patients in the three regions stud-
ied. Our model of sequence divergence among the six
patients who contain the most closely related sequences
(Fig. 5) has permitted us to use all the data to estimate
directly the branch lengths in both the V4-V5 and V3 regions
for each patient (Table 4; Fig. 6). These branch lengths are
obtained from the sum of two components, the first of which
is obtained from the diversity within the sample. The second
component estimates the sequence change which had oc-
curred since the original divergence of these viral genomes
within the infected donor, up to the time the sequences
within each of the current samples began to diverge from
each other.
From this analysis we can show that the earlier component
in fact varies relatively little in the V4-V5 region, by less
than a factor of two (Table 4), and most of the difference
between patients in terms of the overall lengths is contrib-
uted by the sevenfold range in nucleotide diversity among
sequences within each sample. This could have come about
through differences between patients in the rate of nucleo-
tide substitution per virus replication cycle or the rate of
virus replication, or both. In either case, in view of the
genetic similarity of the virus which infected these patients,
the similarity in initial dose, and the duration of the infec-
tion, the difference is likely to reflect differences in the
response of the host to the virus.
The value of the approach we have taken is that, while it
is impossible to determine exactly how long ago the se-
quences within each sample diverged from each other and it
may be different for different patients, the overall divergence
across patients infected by a single donor has accumulated
over approximately 5 years. The HIV sequences received by
each of the six patients shown in Fig. 6, although recently
diverged, would not have been identical at the time of
infection. The extent of this prior divergence, and conse-
quently the time since divergence from the common ances-
tral sequence, is estimated by the difference between the
mean inter- and intrapatient divergence for this group, 8.3
and 4.6%, respectively. The difference of 3.7% is lower than
the mean intrapatient diversity, which implies that at least
half (56%) of the divergence between sequences from dif-
ferent patients, indicated by the branch lengths in Fig. 6 and
Table 4, has occurred in the 5 years since infection, the
remainder having occurred in the infected donor. From this
we estimate the mean rate of nucleotide sequence change in
the V4-V5 and V3 regions to be 0.41 and 0.48% per annum,
respectively. The total time since the cohort sequences
diverged is estimated to be approximately 9 years.
Two earlier estimates of the rate of sequence change in the
env gene of HIV-1, 0.92% (15) and 1.2% (29) on the basis of
sequences from virus isolates, are higher than the estimate
obtained here. Closer comparisons cannot be drawn how-
ever, as there are considerable differences between con-
served and variable regions of the gene (15). Two aspects of
our data suggest that caution should be exercised in extrap-
olating to obtain times of divergence between virus se-
quences from different sources. First, the twofold range over
patients indicates that estimates based on individual patients
or isolates (29) will be subject to large errors. Second, and
perhaps more important, the extreme localization of much of
the variability to very small regions implies that the nucleo-
tide distance between highly diverged sequences will be
consistently underestimated because of saturation effects
which will not be adequately taken into account in whole-
gene analyses.
Nevertheless, taking only the patients within our group,
we can estimate three divergence times. First, the time since
the divergence of the cohort sequence from the related
Edinburgh sequence found in patient 74 would be approxi-
mately 14 years (against 9 years for the cohort). Second, the
time since divergence of the cohort sequence from the
U.S.-derived sequence found in patient 12 could be as much
as 30 years, and third, the time since the divergence from the
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sequence found in patient 82 (and two others, as indicated
above) could be about 24 years. A reasonable interpretation
would be that two HIV-1 lineages which were transmitted
independently from North America are currently repre-
sented in Scotland and have been transmitted to these
hemophiliacs.
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